Melatonin (Liposomal).

Tryptophan is the starting amino acid for the pineal route, moving through 5-HTP and serotonin to melatonin. It feeds endogenous production while the liposomal dose acts at the receptor end.

5-HTP is one enzyme step from serotonin, which is then acetylated and methylated into melatonin. It bypasses the rate-limiting hydroxylation of tryptophan.

Pyridoxal-5-phosphate is the cofactor for the decarboxylase that turns 5-HTP into serotonin upstream of melatonin. Low B6 slows that precursor step.

P5P is the coenzyme form of B6 used directly by aromatic amino acid decarboxylase. It needs no liver conversion before acting on the 5-HTP step.

ASMT methylates N-acetylserotonin into melatonin using SAM as the methyl donor. Methyl group availability is part of endogenous output.

Glycine acts at the NMDA glycine site and widens peripheral blood flow, dropping core temperature. Melatonin signals the same night-time shift through MT1 and MT2 receptors.

Tryptophan is largely consumed by the kynurenine route feeding NAD synthesis. Preformed niacin reduces that pull, leaving more tryptophan for the serotonin and melatonin branch.

Caffeine antagonises adenosine receptors and works against the sleep pressure melatonin signals. Both are cleared by CYP1A2, so caffeine competes for that enzyme and can raise melatonin levels while opposing its effect.

St. John's Wort induces CYP1A2 and CYP3A4, which clear melatonin faster and lower circulating exposure from the same dose.

Montmorency cherry contains melatonin plus tryptophan. Its intake adds to the supplemental dose rather than acting by a separate mechanism.

Magnesium acts as a physiological NMDA receptor blocker and a positive modulator at GABA-A sites, while melatonin works through MT1 and MT2 receptors on circadian timing. The two touch sleep from different directions, which is why they appear together so often. Additive drowsiness is the practical consequence and worth naming before it surprises anyone.

Theanine influences glutamatergic and GABAergic tone and is associated with a relaxed but alert state, whereas melatonin signals biological night. The combination targets falling asleep from two mechanisms rather than one. Neither one is a substitute for the other, and both add to any other calming ingredient in the same formula.

GABA is the main inhibitory neurotransmitter and melatonin's sleep-onset signalling partly involves GABAergic pathways in the hypothalamus. How much orally ingested GABA reaches the brain remains disputed, so this row is honest about the uncertain half. Any drowsiness effects add regardless of which mechanism does the work.

Valerenic acid and related valerian constituents are described as GABA-A modulators, a different target from the melatonin receptors. Sleep formulas commonly stack the two. Additive sedation is the interaction to flag, including with anything else that has a calming effect.

Passionflower extracts are standardised to flavonoids including chrysin and are used in evening formulas alongside melatonin. The mechanisms are separate, so the calming effects add rather than substituting. Evidence for the pairing sits at the formulation and mechanistic level.

Chamomile carries apigenin, a flavone described as binding benzodiazepine sites on the GABA-A receptor. Melatonin does not act there, so the two are complementary in mechanism. Additive drowsiness applies, which matters most for anyone driving in the morning after an evening dose.

Apigenin's affinity for the benzodiazepine site of the GABA-A receptor is characterised in receptor binding work, and it is the constituent behind chamomile's reputation. Combined with melatonin, one ingredient carries the timing signal and the other the inhibitory tone. The pairing is mechanistically coherent, and human evidence for the combination is thin.

Lemon balm constituents, rosmarinic acid among them, are described as inhibiting GABA transaminase, which slows GABA breakdown. That is a separate lever from melatonin receptor signalling. It is a standard evening-formula partner, and the calming effects add.

Honokiol and magnolol are the characterised bioactives of magnolia bark and are described as acting at GABA-A receptors. Melatonin contributes circadian signalling instead. The pairing is common in sleep products and the sedative effects are additive.

A liposome is a phospholipid bilayer vesicle, and phosphatidylcholine is the usual lipid that forms it. Melatonin is amphiphilic enough to sit in both the bilayer and the aqueous core, which is what the delivery form exploits. In a liposomal product the phosphatidylcholine is not an added active, it is the vehicle itself.

Sunflower lecithin supplies the phospholipid fraction that high-pressure homogenisation turns into vesicles, and it is chosen over soy lecithin where soy allergen labelling is a concern. The lecithin quality sets vesicle size and how stable the suspension stays. It is a manufacturing input rather than a co-active.

Liposome bilayers are built from unsaturated phospholipids that oxidise and go rancid, so a lipid-phase antioxidant such as tocopherol is standard in these suspensions. It preserves the vehicle rather than adding to what melatonin does. Its presence on a liposomal label is usually excipient function, not a nutrient dose.

Melatonin is described as a direct radical scavenger and as influencing glutathione-dependent enzyme activity, so the two overlap in the cellular redox network. The co-study record carries the pair in both directions, which is why the polarity here is modulating rather than additive. Both are also common passengers in liposomal formats, so co-formulation is frequent regardless of mechanism.

Alpha-lipoic acid cycles between oxidised and reduced forms in both aqueous and lipid phases, and melatonin is likewise described as active in both compartments. The overlap is redox chemistry read out through markers such as malondialdehyde, not through clinical endpoints. Marker change is what the literature supports here.

Tyrosine feeds dopamine and noradrenaline synthesis, and both are wake-promoting. Taking it near a melatonin dose puts two opposing signals into the same evening. The sensible use is separating them by time of day rather than combining them, and this row exists to flag the conflict.

B12 status has been associated with circadian phase and with melatonin secretion patterns in observational and small experimental work. Association is not causation, and the direction of any effect on an exogenous melatonin dose is not established. It appears in evening formulas on this reasoning and the reasoning is thin.

Inositol appears alongside melatonin in evening powders, where it also serves as a bulking sweetener. There is no settled pharmacological interaction between the two. Naming the pairing as a formulation convention is more honest than inventing a mechanism for it.